mRNA-3927
Sponsors
Moderna Inc., Moderna Therapeutics Inc., ModernaTX, Inc.
Conditions
Propionic Acidemia
Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
RecruitingNCT04159103
Start: 2021-04-15End: 2027-08-31Target: 77Updated: 2026-01-22
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
RecruitingNCT05130437
Start: 2021-11-09End: 2031-12-04Target: 50Updated: 2026-03-23
A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia
RecruitingCTIS2022-502910-10-00
Start: 2025-08-11Target: 32Updated: 2026-01-26
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Not yet recruitingCTIS2022-502911-12-00
Target: 9Updated: 2026-02-24